Regenxbio Inc
Change company Symbol lookup
Select an option...
RGNX Regenxbio Inc
OGSYS Otis Gallery LLC
RDN Radian Group Inc
SLNO Soleno Therapeutics Inc
REI Ring Energy Inc
FSHOX Fidelity® Select Construction & Housing Portfolio
NNN NNN REIT Inc
UTHR United Therapeutics Corp
KEX Kirby Corp
DDOG Datadog Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.

Closing Price
$18.56
Day's Change
1.33 (7.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
18.82
Day's Low
17.05
Volume
(Average)
Volume:
434,410

10-day average volume:
466,934
434,410

DEADLINE ALERT for ALIZY, IVVD, RVYL, and SQ: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

12:15 pm ET March 21, 2023 (Globe Newswire) Print
DEADLINE ALERT for ALIZY, IVVD, RVYL, and SQ: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswireMarch 21, 2023

LOS ANGELES, March 21, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.

Allianz SE (OTC: ALIZY, ALIZF)

Class Period: March 9, 2018 - May 17, 2022

Lead Plaintiff Deadline: April 3, 2023

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Allianz did not have effective internal controls; (2) Allianz's subsidiary was involved in substantial fraudulent activity; (3) as a result, Allianz was at an increased risk of regulatory scrutiny; (4) as a result, Allianz was at an increased risk of substantial losses and financial costs; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are an Allianz shareholder who suffered a loss, click here to participate.

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD)

Class Period: November 29, 2021 - December 14, 2021

Lead Plaintiff Deadline: April 3, 2023

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (2) that defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; (3) that ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are an Invivyd shareholder who suffered a loss, click here to participate.

Ryvyl Inc. f/k/a/ Greenbox POS (NASDAQ: RVYL)

Class Period: January 29, 2021 - January 20, 2023

Lead Plaintiff Deadline: April 3, 2023

The complaint filed in this class action alleges that in the Registration Statement and throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company's financial statements in 2021 and 2022 contained errors resulting in overstatements of revenue, assets, and stockholders' equity and understatements of losses; (2) as a result, Ryvyl would restate certain financials; (3) the Company's internal controls were inadequate; (4) the Company downplayed and obfuscated its internal controls issues; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are a Ryvyl shareholder who suffered a loss, click here to participate.

Block, Inc. f/k/a Square Inc. (NYSE: SQ)

Class Period: November 4, 2021 - April 4, 2022

Lead Plaintiff Deadline: April 3, 2023

The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants did not satisfy the mandatory conditions necessary to exempt them from registration under Section 3(a)(10) and permit the issuance and sale of unregistered Block Shares; (2) in violation of Sections 5(a) and (c) of the Securities Act, no registration statement has been filed with the U.S. Securities and Exchange Commission or been in effect with respect to these Block Shares issued, solicited, and sold by means of Block's January 31, 2022 acquisition and stock-for-stock merger with Afterpay (the "Acquisition"); (3) in order to push the Acquisition through, defendants failed to comply with Section 3(a)(10)'s mandatory preconditions in several respects; and (4) defendants' grossly negligent failures deprived the Supreme Court of New South Wales ("NSW Court") of critical information necessary for any genuine appraisal of the Merger's supposed "fairness," and furthermore deprived plaintiff and other Afterpay shareholders of their statutory right to appear and present to the NSW Court the host of serious concerns and material (yet undisclosed) information ahead of the Acquisition.

If you are a Block shareholder who suffered a loss, click here to participate.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles

Frank R. Cruz, 310-914-5007

fcruz@frankcruzlaw.com

www.frankcruzlaw.com



Primary Logo

comtex tracking

COMTEX_427174998/2010/2023-03-21T12:15:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.